References
- Weber JD , GutmannDH. Deconvoluting mTOR biology. Cell Cycle11, 236–248 (2012).
- Yao JC , ShahMH, ItoTet al. Everolimus for advanced pancreatic neuroendocrine tumors. N. Engl. J. Med.364, 514–523 (2011).
- Motzer RJ , EscudierB, OudardSet al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372, 449–456 (2008).
- Baselga J , CamponeM, PiccartMet al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med.366, 520–529 (2012).
- Motzer RJ , BarriosCH, KimTMet al. Phase II randomized trial comparing sequential first-line everolimus and second-line sunitinib versus first-line sunitinib and second-line everolimus in patients with metastatic renal cell carcinoma. J. Clin. Oncol.32, 2765–2772 (2014).
- Bajetta E , CatenaL, FazioNet al. Everolimus in combination with octreotide long-acting repeatable in a first-line setting for patients with neuroendocrine tumors: an ITMO group study. Cancer120, 2457–2463 (2014).
- Rizzo M , CartenìG, PappagalloG. We need both randomized trials and real-world data: the example of everolimus as second-line therapy for metastatic renal cell carcinoma. Future Oncol.10(12), 1893–1896 (2014).
- Grünwald V , KarakiewiczPI, BavbekSEet al. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy. Eur. J. Cancer.48, 324–332 (2012).
- Albiges L , BergmannL, EymardJCet al. Everolimus for patients with metastatic renal cell carcinoma (mRCC) refractory to anti-VEGF therapy: preliminary results of a pooled analysis of noninterventional studies. J. Clin. Oncol.31(Suppl. 6), (2013). Abstract 392.
- Rizzo M , FacchiniG, SavastanoCet al. Everolimus as second-line therapy for metastatic renal cell carcinoma: a ‘real-life’ study. Future Oncol.11(2), 219–224 (2015).